Develops, licenses, markets and distributes bio-medical and pharmaceutical products and services. The company is principally focused on the development of two emerging drug products for the prevention and treatment of cancer: Topical Interferon Alpha-2b for the treatment of conditions caused by the human papilloma virus, and L-DOS47 drug candidate for the treatment of lung cancer. In addition, the company earns revenue from its drug distribution business in Canada and international licensing arrangements.